Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis.
Conrado DJ, Nicholas T, Tsai K, Macha S, Sinha V, Stone J, Corrigan B, Bani M, Muglia P, Watson IA, Kern VD, Sheveleva E, Marek K, Stephenson DT, Romero K; Critical Path for Parkinson's (CPP) Parkinson's Disease Modeling and Simulation Working Group. Conrado DJ, et al. Among authors: bani m. Clin Transl Sci. 2018 Jan;11(1):63-70. doi: 10.1111/cts.12492. Epub 2017 Jul 27. Clin Transl Sci. 2018. PMID: 28749580 Free PMC article.
Development of a Disease Progression Model for Leucine-Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs.
Ahamadi M, Conrado DJ, Macha S, Sinha V, Stone J, Burton J, Nicholas T, Gallagher J, Dexter D, Bani M, Boroojerdi B, Smit H, Weidemann J, Chen C, Yang M, Maciuca R, Lawson R, Burn D, Marek K, Venuto C, Stafford B, Akalu M, Stephenson D, Romero K; Critical Path for Parkinson's (CPP) Consortium. Ahamadi M, et al. Among authors: bani m. Clin Pharmacol Ther. 2020 Mar;107(3):553-562. doi: 10.1002/cpt.1634. Epub 2019 Dec 5. Clin Pharmacol Ther. 2020. PMID: 31544231 Free PMC article.
A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation.
Ahamadi M, Mehrotra N, Hanan N, Lai Yee K, Gheyas F, Anton J, Bani M, Boroojerdi B, Smit H, Weidemann J, Macha S, Thuillier V, Chen C, Yang M, Williams-Gray CH, Stebbins GT, Pagano G, Hang Y, Marek K, Venuto CS, Javidnia M, Dexter D, Pedata A, Stafford B, Akalu M, Stephenson D, Romero K, Sinha V; Critical Path for Parkinson’s Consortium. Ahamadi M, et al. Among authors: bani m. Clin Pharmacol Ther. 2021 Aug;110(2):508-518. doi: 10.1002/cpt.2277. Epub 2021 Jun 12. Clin Pharmacol Ther. 2021. PMID: 33894056
Association between amygdala reactivity and a dopamine transporter gene polymorphism.
Bergman O, Åhs F, Furmark T, Appel L, Linnman C, Faria V, Bani M, Pich EM, Bettica P, Henningsson S, Manuck SB, Ferrell RE, Nikolova YS, Hariri AR, Fredrikson M, Westberg L, Eriksson E. Bergman O, et al. Among authors: bani m. Transl Psychiatry. 2014 Aug 5;4(8):e420. doi: 10.1038/tp.2014.50. Transl Psychiatry. 2014. PMID: 25093598 Free PMC article.
Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo.
Furmark T, Appel L, Michelgård A, Wahlstedt K, Ahs F, Zancan S, Jacobsson E, Flyckt K, Grohp M, Bergström M, Pich EM, Nilsson LG, Bani M, Långström B, Fredrikson M. Furmark T, et al. Among authors: bani m. Biol Psychiatry. 2005 Jul 15;58(2):132-42. doi: 10.1016/j.biopsych.2005.03.029. Biol Psychiatry. 2005. PMID: 16038684 Clinical Trial.
A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety.
Furmark T, Appel L, Henningsson S, Ahs F, Faria V, Linnman C, Pissiota A, Frans O, Bani M, Bettica P, Pich EM, Jacobsson E, Wahlstedt K, Oreland L, Långström B, Eriksson E, Fredrikson M. Furmark T, et al. Among authors: bani m. J Neurosci. 2008 Dec 3;28(49):13066-74. doi: 10.1523/JNEUROSCI.2534-08.2008. J Neurosci. 2008. PMID: 19052197 Free PMC article. Clinical Trial.
313 results